"Janus Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit JANUS KINASES.
| Descriptor ID |
D000075242
|
| MeSH Number(s) |
D27.505.519.389.755.500
|
| Concept/Terms |
Janus Kinase Inhibitors- Janus Kinase Inhibitors
- Inhibitors, Janus Kinase
- Kinase Inhibitors, Janus
- JAK Inhibitors
- Inhibitors, JAK
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase Inhibitors".
This graph shows the total number of publications written about "Janus Kinase Inhibitors" by people in this website by year, and whether "Janus Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 2 | 0 | 2 |
| 2018 | 13 | 3 | 16 |
| 2019 | 3 | 2 | 5 |
| 2020 | 12 | 19 | 31 |
| 2021 | 11 | 4 | 15 |
To return to the timeline, click here.
Below are the most recent publications written about "Janus Kinase Inhibitors" by people in Profiles.
-
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future? Arthritis Rheumatol. 2021 12; 73(12):2166-2178.
-
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. Eur Respir J. 2021 10; 58(4).
-
Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19. Curr Opin Crit Care. 2021 10 01; 27(5):493-496.
-
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021 Nov; 40(11):4671-4674.
-
The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). Leukemia. 2021 10; 35(10):2917-2923.
-
Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study. Arthritis Care Res (Hoboken). 2021 09; 73(9):1322-1331.
-
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021 Oct; 99:108027.
-
Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J Am Geriatr Soc. 2021 10; 69(10):2752-2758.
-
Janus kinase inhibitors in dermatology: Part II. A comprehensive review. J Am Acad Dermatol. 2022 02; 86(2):414-422.
-
Audio Interview: Covid-19 in Children. N Engl J Med. 2021 06 17; 384(24):e108.